Alnylam Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Sorrento Therapeutics, Moderna and Regulus Therapeutics.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. | |
Founding Date | Founding Date 2002 | Founding Date 2006 | Founding Date 2010 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations San Diego, US HQ San Diego, US | Locations San Diego, US HQ | ||
Employees | Employees 1,32324% increase | Employees 31019% decrease | Employees 5,60044% increase | Employees 2462% decrease |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 1.5 m | Valuation ($) 21.2 b | Valuation ($) 105.4 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $6.8b (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods $4.7b (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit $2.2b (FY, 2023) | Gross profit N/A |
Net income | Net income ($440.2m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income ($4.7b) (FY, 2023) | Net income ($30m) (FY, 2023) |
Operating ⚠ | ||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued 270 (FY, 2020) | Patents Issued 300 (FY, 2016) |
Funding | ||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 42.6m | Total funding raised $ 1.8b | Total funding raised $ 10m |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyModerna
HQ
Cambridge, US
Employees
5,600↑ 44% increase
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
View companyRegulus Therapeutics
HQ
San Diego, US
Employees
24
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View company